Table 5.

Reasons for Imatinib Discontinuation Documented for Patients Who Had Dose Escalations in the International Randomized Study of Interferon and STI571 Study (N = 106)

Variable	No. (%)
Remained on imatinib at data cutoff	42 (40)
Patients receiving ≥600 mg/d dose at cutoff	31 (29)
Discontinued imatinib*	64 (60)
Unsatisfactory effect†	36 (34)
Protocol violation	4 (4)
Adverse event(s)	2 (2)
Abnormal procedure	2 (2)
Withdrawal of consent	5 (5)
Administrative problems/lost to follow-up	2 (2)
BMT (no longer required study drug)	6 (6)
Crossed over to IFN-α plus cytarabine	7 (7)

BMT indicates bone marrow transplantation; IFN-α, interferon alpha.

^*Discontinued on or before January 31, 2007.

^†Patients who discontinued because of unsatisfactory therapeutic effect were on imatinib study treatment for a median of 47 months (range, 8.3– 72.9 months).